UNMC team develops long-acting nanomedicines for HIV infection
Injection would be significant improvement over daily regimen of pills
This has been a good week for breakthroughs in HIV/AIDS.
Earlier this week, the Food and Drug Administration approved a daily pill, Truvada, which reduces the risk of HIV infection. Today, a University of Nebraska Medical Center research team’s progress toward developing weekly or twice-monthly injectable antiretroviral therapy (ART) nanomedicines for patients with human immunodeficiency virus (HIV) infection will be
- Published in Regional News
- Be the first to comment!